Clinical Trials Logo
  1. Home
  2. Colorectal Cancer (CRC)
  3. NCT00165854

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

Colorectal Cancer (CRC) Clinical Trial

Clinical Trial Summary

Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00165854
Study type Interventional
Source Eisai Inc.
Contact
Status Completed
Phase Phase 2
Start date March 2003
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Completed NCT01450319 - A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype Phase 2
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Recruiting NCT04083599 - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors Phase 1/Phase 2
Completed NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT03253185 - A Study of SC-007 in Subjects With Advanced Cancer Phase 1
Completed NCT00851045 - Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer Phase 2
Recruiting NCT06026410 - KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Phase 1
Recruiting NCT04622423 - Advanced Therapies for Liver Metastases
Active, not recruiting NCT02955940 - An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Phase 2
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Completed NCT03314935 - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Phase 1/Phase 2
Recruiting NCT05379985 - Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Phase 1
Recruiting NCT05648955 - Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment Early Phase 1
Recruiting NCT05706129 - A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02646748 - Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Phase 1
Not yet recruiting NCT02005913 - A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence N/A
Recruiting NCT04256707 - Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Phase 1/Phase 2
Recruiting NCT04792684 - Collection of Samples USOPTIVAL Study
Completed NCT00483080 - Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) Phase 2